Discontinued — last reported Q4 '25
Astera Labs, Inc. Cash, Cash Equivalents, and Marketable Securities increased by 1.5% to $1.04B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 15.6%, from $896.18M to $1.04B. Over 2 years (FY 2023 to FY 2025), Cash, Cash Equivalents, and Marketable Securities shows an upward trend with a 210.8% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Higher levels indicate strong liquidity and financial health, while lower levels may signal a need for external financing.
This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term invest...
A standard liquidity metric reported by virtually all public companies on the balance sheet.
cash_equivalents_marketable_securities_total| Q1 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $105.69M | $105.69M | $794.10M | $816.39M | $866.94M | $894.35M | $896.18M | $1.03B | $1.11B | $1.02B | $1.04B |
| QoQ Change | — | +0.0% | +651.3% | +2.8% | +6.2% | +3.2% | +0.2% | +14.5% | +8.0% | -7.9% | +1.5% |
| YoY Change | — | — | +651.3% | — | — | +746.2% | +12.9% | +25.7% | +27.9% | +14.2% | +15.6% |